Vera Therapeutics Shares Rally After Strong Interim eGFR Results Surface in FDA Review
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.
/ 5 items
#VERA↓
Vertex's Povetacicept Delivers Solid IgAN Data — But No Real Threat to Vera's Atacicept, Says BofA
BofA reaffirms Buy on Vera Therapeutics; Vertex’s povetacicept Phase 3 interim results in IgAN meet expectations but pose no major competitive threat.
FDA Grants Priority Review for Atacicept IgAN Treatment
Vera Therapeutics receives FDA Priority Review for atacicept, a potential first-in-class treatment for IgA nephropathy with a decision expected by July 2026.
H.C. Wainwright Raises Vera Therapeutics Price Target to $90 After ORIGIN 3 Data
Vera Therapeutics has submitted its application for atacicept, a potential breakthrough IgAN treatment that successfully reduced proteinuria in the Phase 3 ORIGIN 3 trial.
BofA Sees Big Potential in Vera Therapeutics' Autoimmune Drug
Bank of America starts coverage on Vera Therapeutics with Buy rating and $48 target, citing Atacicept's potential in multibillion-dollar autoimmune disease market.